2型糖尿病合并非酒精性脂肪性肝病药物治疗研究进展

Progress in the study of pharmacologic treatment of type 2 diabetes mellitus combined with non-alcoholic fatty liver disease

2型糖尿病(T2DM)和非酒精性脂肪性肝病(NAFLD)在全球范围内流行。T2DM与NAFLD、非酒精性脂肪肝炎(NASH)、肝纤维化、肝硬化和肝细胞癌的发展有关,而NAFLD患者发生T2DM的风险也升高。鉴于这两种疾病间复杂的关系,其治疗需要结合生活方式、饮食、药物等多方面考虑。本文主要总结了生活方式、饮食、目前抗糖尿病药物对脂肪肝的影响以及新的潜在治疗靶点,对2型糖尿病合并非酒精性脂肪性肝病药物治疗进展作一综述。

Type 2 diabetes mellitus(T2DM)and non-alcoholic fatty liver disease(NAFLD)are prevalent worldwide,and T2DM is associated with the development of NAFLD,non-alcoholic steatohepatitis(NASH),hepatic fibrosis,cirrhosis,and hepatocellular carcinoma,whereas patients with NAFLD have an elevated risk of developing T2DM.Given the complex relationship between these two diseases,their treatment requires a combination of lifestyle,dietary,and pharmacologic considerations.This article mainly summarizes the effects of lifestyle,diet,current antidiabetic drugs on fatty liver,and new potential therapeutic targets.